新预后模型识别可能从治愈性治疗中获益的80岁及以上弥漫大B细胞淋巴瘤患者:西班牙GELTAMO组多中心回顾性分析
该多中心回顾性分析纳入19家医院252例80-100岁弥漫大B细胞淋巴瘤或3B级滤泡性淋巴瘤患者,中位随访44个月,中位无进展生存期和总生存期分别为9.5和12.5个月。基于108例接受R-CHOP样方案治疗患者的多因素分析建立预后模型,0-1个与2-3个危险因素患者的中位总生存期分别为45个月与12个月(P=0.001)。
要点
- 163例(63%)接受含蒽环类和/或利妥昔单抗的化疗,15%未接受化疗。
- 年龄<86岁、CIRS评分<6、R-IPI中危(1-2分)及全量或减量R-CHOP治疗与更好的PFS和OS独立相关。
- 基于年龄>85岁、R-IPI 3-5分或CIRS>5分构建的预后模型可能有助于选择可从治愈性治疗中获益的患者,但需在更大系列中验证。
核心结论
- R-CHOP样治疗与相当比例患者的良好生存相关。
- 已开发一个简单的预后模型,可能有助于选择可从治愈性治疗中获益的患者,但需在更大系列中验证。
研究设计与样本
- 西班牙GELTAMO组的多中心回顾性分析,纳入19家医院252例80-100岁诊断为弥漫大B细胞淋巴瘤或3B级滤泡性淋巴瘤的患者。
- 主要目的是分析治疗类型和合并症量表对无进展生存期和总生存期的影响。
主要发现
- 163例(63%)接受含蒽环类和/或利妥昔单抗的化疗,15%未接受化疗。
- 中位随访44个月,中位无进展生存期和总生存期分别为9.5和12.5个月。
- 在205例接受任何化疗的患者中,合并症量表未显著影响治疗类型的选择。
- 与更好PFS和OS独立相关的因素为:年龄<86岁、CIRS评分<6、R-IPI中危(1-2分)、全量或减量R-CHOP治疗。
- 在108例接受R-CHOP样治疗的患者中,0-1个与2-3个危险因素(年龄>85岁、R-IPI 3-5分或CIRS>5分)患者的中位OS分别为45个月与12个月(P=0.001)。
关键数值与推荐
- 预后模型危险因素:年龄>85岁、R-IPI 3-5分或CIRS>5分。
- 0-1个危险因素患者中位OS为45个月,2-3个危险因素患者中位OS为12个月(P=0.001)。
临床怎么用
- 作者认为R-CHOP样治疗与相当比例患者的良好生存相关。
- 作者认为该简单预后模型可能有助于选择可从治愈性治疗中获益的患者,但需在更大系列中验证。
局限性
- 原文指出该预后模型需在更大系列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The means of optimally managing very elderly patients with diffuse large B-cell lymphoma (DLBCL) has not been established. We retrospectively analyzed 252 patients aged 80-100 years, diagnosed with DLBCL or grade 3B follicular lymphoma, treated in 19 hospitals from the GELTAMO group. Primary objective was to analyze the influence of the type of treatment and comorbidity scales on progression-free survival (PFS) and overall survival (OS). One hundred sixty-three patients (63%) were treated with chemotherapy that included anthracyclines and/or rituximab, whereas 15% received no chemotherapeutic treatment. With a median follow-up of 44 months, median PFS and OS were 9.5 and 12.5 months, respectively. In an analysis restricted to the 205 patients treated with any kind of chemotherapy, comorbidity scales did not influence the choice of treatment type significantly. Independent factors associated with better PFS and OS were: age < 86 years, cumulative illness rating scale (CIRS) score < 6, intermediate risk (1-2) R-IPI, and treatment with R-CHOP at full or reduced doses. We developed a prognostic model based on the multivariate analysis of the 108 patients treated with R-CHOP-like: median OS was 45 vs. 12 months (P = .001), respectively, for patients with 0-1 vs. 2-3 risk factors (age > 85 years, R-IPI 3-5 or CIRS > 5). In conclusion, treatment with R-CHOP-like is associated with good survival in a significant proportion of patients. We have developed a simple prognostic model that may aid the selection patients who could benefit from a curative treatment, although it needs to be validated in larger series.
引用
- Pardal E, Díez Baeza E, Salas Q, et al. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group. Am J Hematol. 2018. PMID: 29658143. doi:10.1002/ajh.25107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。